CoChat

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

Open access
Stroes, Erik S., Thompson, Paul D., Corsini, Alberto, Vladutiu, Georgirene D., Raal, Frederick J., Ray, Kausik K., Roden, Michael, Stein, Evan, Tokgözoğlu, Lale, Nordestgaard, Børge G., Bruckert, Eric, De Backer, Guy, Krauss, Ronald M., Laufs, Ulrich, Santos, Raul D., Hegele, Robert A., Hovingh, G. Kees, Leiter, Lawrence A., Mach, Francois, März, Winfried, Newman, Connie B., Wiklund, Olov, Jacobson, Terry A., Catapano, Alberico L., Chapman, M. John, Ginsberg, Henry N., European Atherosclerosis Society Consensus Panel, Stroes, Erik, Thompson, Paul D., Corsini, Alberto, Vladutiu, Georgirene D., Raal, Frederick J., Ray, Kausik K., Roden, Michael, Stein, Evan, Tokgözoğlu, Lale, Nordestgaard, Børge G., Bruckert, Eric, Krauss, Ronald M., Laufs, Ulrich, Santos, Raul D., März, Winfried, Newman, Connie B., John Chapman, M., Ginsberg, Henry N., John Chapman, M., Ginsberg, Henry N., de Backer, Guy, Catapano, Alberico L., Hegele, Robert A., Kees Hovingh, G., Jacobson, Terry A., Leiter, Lawrence, Mach, Francois, Wiklund, Olov · 2015 · European Heart Journal

The DOI matches its Crossref record; 120 of the 124 references it cites were found in a registry or an index; 24 of the 148 sources its claims cite were checked for support.

Abstract

Statin-associated muscle symptoms (SAMS) are one of the principal reasons for statin non-adherence and/or discontinuation, contributing to adverse cardiovascular outcomes. This European Atherosclerosis Society (EAS) Consensus Panel overviews current understanding of the pathophysiology of statin-associated myopathy, and provides guidance for diagnosis and management of SAMS. Statin-associated myopathy, with significant elevation of serum creatine kinase (CK), is a rare but serious side effect of statins, affecting 1 per 1000 to 1 per 10 000 people on standard statin doses. Statin-associated muscle symptoms cover a broader range of clinical presentations, usually with normal or minimally elevated CK levels, with a prevalence of 7-29% in registries and observational studies. Preclinical studies show that statins decrease mitochondrial function, attenuate energy production, and alter muscle protein degradation, thereby providing a potential link between statins and muscle symptoms; controlled mechanistic and genetic studies in humans are necessary to further understanding. The Panel proposes to identify SAMS by symptoms typical of statin myalgia (i.e. muscle pain or aching) and their temporal association with discontinuation and response to repetitive statin re-challenge. In people with SAMS, the Panel recommends the use of a maximally tolerated statin dose combined with non-statin lipid-lowering therapies to attain recommended low-density lipoprotein cholesterol targets. The Panel recommends a structured work-up to identify individuals with clinically relevant SAMS generally to at least three different statins, so that they can be offered therapeutic regimens to satisfactorily address their cardiovascular risk. Further research into the underlying pathophysiological mechanisms may offer future therapeutic potential.

Overview

CoChat Summary

TL;DR

This European Atherosclerosis Society Consensus Panel statement reviews statin-associated muscle symptoms (SAMS), their assessment, aetiology, and management. It proposes a clinical definition based on symptoms and temporal association with statin discontinuation/re-challenge, and recommends maximally tolerated statin doses plus non-statin lipid-lowering therapies to achieve LDL-C targets.

Key findings

  • Statin-associated myopathy with significant CK elevation is rare, affecting 1 per 1000 to 1 per 10 000 people on standard statin doses; myopathy with CK >10× ULN occurs in approximately 1 per 10 000 per year, and rhabdomyolysis in ∼1 in 100 000 per year.
  • SAMS are much more common in registries and observational studies, with a prevalence of 7–29%, usually with normal or minimally elevated CK; they contribute to statin discontinuation, which can be up to 75% within 2 years, and in 65% of former statin users the main reason for non-adherence/discontinuation was side effects, predominantly muscle-related.
  • In the STOMP randomized trial of 420 statin-naïve subjects, 9.4% of atorvastatin 80 mg-treated and 4.6% of placebo subjects met the study definition of myalgia (P = 0.054), with no differences in muscle strength or exercise performance.
  • Management recommendations include using a maximally tolerated statin dose, switching statins, alternate-day or twice-weekly dosing (which reduced LDL-C by 12–38% and was tolerated by ∼70% of previously intolerant patients), and adding non-statin therapies such as ezetimibe (LDL-C reduction 15–20%).

Methods

  • Design: European Atherosclerosis Society Consensus Panel statement providing an overview of pathophysiology and guidance for diagnosis and management of SAMS.
  • Data/sample: Narrative synthesis of randomized controlled trials, patient registries, observational studies, preclinical studies, and genetic studies; no new primary patient sample was collected.
  • Analysis: Expert consensus; the Panel proposes SAMS definitions by CK categories and a therapeutic flow-chart based on symptoms, CK levels, and temporal association with statin initiation, discontinuation, and re-challenge.

Limitations

  • The paper states that a definitive diagnosis of SAMS is difficult because symptoms are subjective, there is no gold standard diagnostic test, and there is no validated muscle symptom questionnaire.
  • The paper notes that observational studies lack a placebo comparator, so causality cannot be established, while RCTs may underrepresent patients with comorbidities predisposing to musculoskeletal symptoms and do not always incorporate dedicated muscle-complaint questionnaires.
  • Evident from the text: this is a consensus statement rather than a systematic review or meta-analysis, and several recommendations rely on expert opinion and limited or conflicting evidence, including insufficient evidence to recommend genetic testing as part of routine SAMS work-up.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehv043

Cites

120 of 120 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Trends in statin use (upper panel) and statin non-adherence/discontinuation (lower panel) in adults ≥40 years, in Denmark over the period 1995–2010. Statin use from 1 January 1995 to 31 December 2010 was classified according to the Anatomical Therapeutic Classification of Drugs code C10AA, as registered in the national Danish Registry of Medicinal Products Statistics, recording information on all prescribed drugs dispensed at all Danish pharmacies from 1995 onwards (for details see references26,27). The percentage of the Danish population aged ≥40 years on statins increased from <1% in 1995 to 11% in 2010. Correspondingly, non-adherence or discontinuation (defined as the percentage of patients starting statins who only redeemed one prescription) increased from 2% in 1995 to 13% in 2010. Figure designed by Dr Sune F. Nielsen and Prof Børge G. Nordestgaard.
Figure 1 Trends in statin use (upper panel) and statin non-adherence/discontinuation (lower panel) in adults ≥40 years, in Denmark over the period 1995–2010. Statin use from 1 January 1995 to 31 December 2010 was classified according to the Anatomical Therapeutic Classification of Drugs code C10AA, as registered in the national Danish Registry of Medicinal Products Statistics, recording information on all prescribed drugs dispensed at all Danish pharmacies from 1995 onwards (for details see references26,27). The percentage of the Danish population aged ≥40 years on statins increased from <1% in 1995 to 11% in 2010. Correspondingly, non-adherence or discontinuation (defined as the percentage of patients starting statins who only redeemed one prescription) increased from 2% in 1995 to 13% in 2010. Figure designed by Dr Sune F. Nielsen and Prof Børge G. Nordestgaard.CC BY-NC · PubMed Central
Figure 2 Therapeutic flow-chart for management of patients with statin-associated muscle symptoms.
Figure 2 Therapeutic flow-chart for management of patients with statin-associated muscle symptoms.CC BY-NC · PubMed Central
Figure 3 Effects potentially involved in statin-related muscle injury/symptoms (Reproduced with permission from Needham and Mastaglia 2014).79 A number of statin-mediated effects have been proposed including reduced levels of non-cholesterol end-products of the mevalonate pathway; reduced sarcolemmal and/or sarcoplasmic reticular cholesterol; increased myocellular fat and/or sterols; inhibition of production of prenylated proteins or guanosine triphosphate (GTP)ases; alterations in muscle protein catabolism; decreased myocellular creatine; changes in calcium homeostasis; immune-mediated effects of statins and effects on mitochondrial function—see Figure 4 and Box 4. Ca2+ATPase, calcium ATPase; HMG CoA, 3-hydroxy-3-methyl-glutaryl-CoA; PP, pyrophosphate.
Figure 3 Effects potentially involved in statin-related muscle injury/symptoms (Reproduced with permission from Needham and Mastaglia 2014).79 A number of statin-mediated effects have been proposed including reduced levels of non-cholesterol end-products of the mevalonate pathway; reduced sarcolemmal and/or sarcoplasmic reticular cholesterol; increased myocellular fat and/or sterols; inhibition of production of prenylated proteins or guanosine triphosphate (GTP)ases; alterations in muscle protein catabolism; decreased myocellular creatine; changes in calcium homeostasis; immune-mediated effects of statins and effects on mitochondrial function—see Figure 4 and Box 4. Ca2+ATPase, calcium ATPase; HMG CoA, 3-hydroxy-3-methyl-glutaryl-CoA; PP, pyrophosphate.CC BY-NC · PubMed Central
Figure 4 Possible targets of statins in the mitochondrion with deleterious effects on muscle function. The interaction of statins with muscle mitochondria can involve (i) reduced production of prenylated proteins including the mitochondrial electron transport chain (ETC) protein, ubiquinone (coenzyme Q10), (ii) subnormal levels of farnesyl pyrophosphate and geranylgeranyl pyrophosphate leading to impaired cell growth and autophagy, (iii) low membrane cholesterol content affecting membrane fluidity and ion channels, and (iv) the triggered calcium release from the sarcoplasmic reticulum via ryanodine receptors, resulting in impaired calcium signalling.92–94 Statin-induced depletion of myocellular ubiquinone, an essential coenzyme which participates in electron transport during oxidative phosphorylation,95 may attenuate electron transfer between complexes I, III, and II of ETC. ADP, adenosine diphosphate; ATP, adenosine triphosphate; Cyt C, cytochrome C; FAD, flavin adenine dinucleotide; FADH2, flavin adenine dinucleotide reduced; MPT, mitochondrial permeability transition; MtDNA, mitochondrial DNA; NAD, nicotinamide adenine dinucleotide; NADH, nicotinamide adenine dinucleotide; ROS, reactive oxidative species; TCA cycle, tricarboxylic acid cycle.
Figure 4 Possible targets of statins in the mitochondrion with deleterious effects on muscle function. The interaction of statins with muscle mitochondria can involve (i) reduced production of prenylated proteins including the mitochondrial electron transport chain (ETC) protein, ubiquinone (coenzyme Q10), (ii) subnormal levels of farnesyl pyrophosphate and geranylgeranyl pyrophosphate leading to impaired cell growth and autophagy, (iii) low membrane cholesterol content affecting membrane fluidity and ion channels, and (iv) the triggered calcium release from the sarcoplasmic reticulum via ryanodine receptors, resulting in impaired calcium signalling.92–94 Statin-induced depletion of myocellular ubiquinone, an essential coenzyme which participates in electron transport during oxidative phosphorylation,95 may attenuate electron transfer between complexes I, III, and II of ETC. ADP, adenosine diphosphate; ATP, adenosine triphosphate; Cyt C, cytochrome C; FAD, flavin adenine dinucleotide; FADH2, flavin adenine dinucleotide reduced; MPT, mitochondrial permeability transition; MtDNA, mitochondrial DNA; NAD, nicotinamide adenine dinucleotide; NADH, nicotinamide adenine dinucleotide; ROS, reactive oxidative species; TCA cycle, tricarboxylic acid cycle.CC BY-NC · PubMed Central

Verification

Claims the paper makes

13 Valid · 4 Not valid · 72 Not checked · 29 Own results and interpretations

72 more claims · 6 with their cited sources checked

Create a free account to see all 118 claims and to verify the 124 references still open.

See all claims — free account
  • It may state two separate claims as one. 35
  • Probably not a substantial claim. 9

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 120 references

Research works printed but not linked: 1

  1. Vladutiu, 2014, Inborn errors of muscle metabolism implicated in risk for statin-induced myopathy, Molec Genet Metab, 111, 264

Cited by

See all 1,443

Metadata

Authors
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., Bruckert, E., De Backer, G., Krauss, R. M., Laufs, U., Santos, R. D., Hegele, R. A., Hovingh, G. K., Leiter, L. A., Mach, F., März, W., Newman, C. B., Wiklund, O., Jacobson, T. A., Catapano, A. L., Chapman, M. J., Ginsberg, H. N., European Atherosclerosis Society Consensus Panel, Stroes, E., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., Bruckert, E., Krauss, R. M., Laufs, U., Santos, R. D., März, W., Newman, C. B., John Chapman, M., Ginsberg, H. N., John Chapman, M., Ginsberg, H. N., de Backer, G., Catapano, A. L., Hegele, R. A., Kees Hovingh, G., Jacobson, T. A., Leiter, L., Mach, F., & Wiklund, O.
Affiliations
  • Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
  • Academic Medical Center, University of Amsterdam, The Netherlands
  • Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, St. Michael's Hospital, University of Toronto, Canada
  • INSERM, Pitié-Salpetriere University Hospital, Paris, France
  • Amsterdam UMC Location University of Amsterdam (NL)
Venue
European Heart Journal
Published
2015-02-18
Volume
36
Issue
17
Pages
1012-1022
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2134159541
Cited by
1,443
References
124
Citations by year
2026: 103 · 2025: 109 · 2024: 112 · 2023: 103 · 2022: 118 · 2021: 152 · 2020: 122 · 2019: 134 · 2018: 127 · 2017: 143 · 2016: 161 · 2015: 54
FWCI
162.77
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
  • Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • Spiral (Imperial College London) (submittedVersion, other-oa)
Funders
  • Amgen
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • F. Hoffmann-La Roche
  • Danone
  • Regeneron Pharmaceuticals
  • Valeant Pharmaceuticals International
  • Quest Diagnostics
  • Kowa Company
  • European Atherosclerosis Society
  • Servier
  • Esperion Therapeutics
  • Genentech
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
statin-associated muscle symptoms, statin-induced myopathy, statin intolerance, statin rechallenge, statin discontinuation, creatine kinase elevation, mitochondrial dysfunction, muscle protein degradation, statin dose reduction, non-statin lipid-lowering therapy, LDL cholesterol targets, cardiovascular risk
MeSH terms
Proprotein Convertase 9, Complementary Therapies, Hypolipidemic Agents, Creatine Kinase, Diet, Humans, Mitochondria, Muscle, Muscular Diseases, Risk Factors, Serine Endopeptidases, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Genetic Predisposition to Disease, Mitochondrial Diseases, Consensus, Proprotein Convertases, Cholesterol Ester Transfer Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. https://app.cochat.ai/papers/10.1093/eurheartj/ehv043
The paper
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., Bruckert, E., De Backer, G., Krauss, R. M., Laufs, U., Santos, R. D., Hegele, R. A., Hovingh, G. K., Leiter, L. A., Mach, F., . . . Wiklund, O. (2015). Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal. https://doi.org/10.1093/eurheartj/ehv043

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.